Additionally, SERCA2 expression and activity are decreased in rodent and human HF studies and are a potential therapeutic target to augment cardiac function in HF patients (ClinicalTrials.gov: NCT04703842) (Eisner et al. 2013; Greenberg et al. 2016; Hasenfuss et al. 1994; Romeo et al. 2023). This evidence concerns the gene ATP2A2 and hydrops fetalis.